Name: Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course
Uploaded: 2026-03-25T00:00:00.000Z

Join the leading experts as they go in-depth on some of the most important topics in dermatology. Hear invaluable insights on mechanism of disease, treatment options, and more for some of the most challenging dermatologic conditions.

Discourses in Dermatology

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

Hidradenitis Suppurativa

Remibrutinib is a novel oral highly selective Bruton's tyrosine kinase inhibitor designed to prevent mast cell mediated release of histamine and other pro inflammatory mediators. Remix 1 and Remix 2 were multicenter randomized double blind placebo controlled phase three studies. Patients were randomized two to one to receive revibrutinib 25mg BID or placebo for 24 weeks followed by an open label period in which all patients received remibrutinib through week 52. This pooled analysis included 606 patients in the remibrutinib group and 306 in the placebo group with well balanced baseline characteristics. Remibrutinib demonstrated rapid improvement in disease activity compared with placebo. Reductions in the weekly urticaria activity score or UA as 7 were observed as early as week one with mean change from baseline of negative 11.8 versus negative 3.6 for placebo. The treatment difference continued through week 24 with the changes of negative 22.4 for imibutinib versus 15.4 for placebo. Similar early improvements were seen with itch and high severity scores. At week one, the mean change in weekly itch severity score was minus 5.3 with remibrutinib compared with minus 1.8 for placebo and high severity scores improved by negative 6.4 versus negative 1.8 respectively. Importantly, these benefits were sustained through 52 weeks. Patients who initiated remibrutinib at baseline and those who transitioned from placebo achieved comparable reductions in in the UAS 7, ISS 7 and HSS 7 by the end of the study. Remibroutinib also demonstrated favorable safety and tolerability across both studies. No deaths were reported, serious adverse events were infrequent and none were considered related to the study medication by investigators. The most common treatment emergent adverse events included COVID 19, nasopharyngitis and headache. In conclusion, pooled Remix 1 and Remix 2 data showed that remibrutinib provides rapid and sustained symptom relief with a favorable safety profile in patients with CSU inadequately controlled by antihistamines. So it's wonderful to be able to offer our patients an FDA approved oral medication which works quickly as in seven days and there's a reduction in both highs and itch with a reassuring safety profile.

When does timing actually change outcomes in hidradenitis suppurativa?&nbsp;Dr. Brownstone walks through why earlier intervention with secukinumab may shift the trajectory, not just the symptoms.In this overview, Nicholas Brownstone, MD, focuses on a post hoc analysis from the SUNSHINE and SUNRISE trials, looking at how disease duration and severity shape response to secukinumab. The signal is consistent: patients treated earlier in their disease course, particularly those with less advanced Hurley staging, were more likely to reach higher thresholds of response, including HiSCR100. &nbsp;It’s a useful reframing of a familiar challenge in HS. Not just whether a therapy works, but when it’s introduced, and what may be lost as disease progresses. Watch the breakdown, then explore the <a target="_blank" rel="noopener noreferrer" href="https://dermsquared.com/news-research/early-treatment-hidradenitis-suppurativa">full poster</a> for a closer look at the data.&nbsp;

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

Related CME